cells

Hepion Pharmaceuticals

US: HEPA

$74m market cap

$2.3 last close

Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for chronic liver disease. The company’s lead asset is CRV431, a cyclophilin inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH).

Investment summary

Hepion has announced interim results from its ongoing Phase IIa study of CRV431 in non-alcoholic steatohepatitis (NASH). The preliminary results are from the low-dose arm of the study (75mg, n=12) and showed a 18.4% decline in alanine aminotransferase (ALT) and a 12.1% decline in aspartate aminotransferase (AST) liver biomarkers after 28 days. Although these data were underpowered for significance, this is the first indication of meaningful clinical activity in this patient group. This is the first look at the potential for this drug and, although small, it is very encouraging.

Y/E Dec
Revenue (US$m)
EBITDA (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.0 (14.3) (9.8) (5018.18) N/A N/A
2019A 0.0 (7.7) (7.9) (326.09) N/A N/A
2020E 0.0 (17.2) (17.5) (165.41) N/A N/A
2021E 0.0 (18.5) (18.5) (57.93) N/A N/A
Register to receive research on Hepion Pharmaceuticals as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (US$m) 42.6
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 9.0 (32.1) (58.3)
Relative* 4.5 (39.4) (64.1)
52-week high/low US$5.7/US$1.1
*% relative to local index
Key management
Robert Foster CEO
John Cavan FD